EFLORNITHINE
Manner of administration:Oral
Restriction
Indication: High-risk neuroblastoma
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 3 | Max qty units: 300 | # of repeats: 2 | DPMQ: $34,622.40 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Ifinwil | |||||
Manner of administration:Oral
Restriction
Indication: High-risk neuroblastoma
Treatment phase: Continuing treatment
Restriction
Indication: High-risk neuroblastoma
Treatment phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 3 | Max qty units: 300 | # of repeats: 2 | DPMQ: $34,622.40 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Ifinwil | |||||
Manner of administration:Oral
Restriction
Indication: High-risk neuroblastoma
Treatment phase: Continuing treatment
Restriction
Indication: High-risk neuroblastoma
Treatment phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 3 | Max qty units: 300 | # of repeats: 2 | DPMQ: $34,671.27 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Ifinwil | |||||
Manner of administration:Oral
Restriction
Indication: High-risk neuroblastoma
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 3 | Max qty units: 300 | # of repeats: 2 | DPMQ: $34,671.27 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Ifinwil | |||||